Xbrane Welcomes Milestone In $14bn Nivolumab Journey, Partner Sought
Potential For Clinical Trials In H1 2025; Commercialization Deal Due Later This Year
In a for-now limited pool of chasers, Sweden’s Xbrane Biopharma has unveiled a milestone and business update for its proposed biosimilar to Bristol Myers Squibb’s major PD-1 inhibitor, Opdivo.
